US TRIALS OF ALPIDEM HALTED
The pharmaceutical unit of L'Oreal, Synthelabo SA, suffered an unexpected plunge in its share price last week on news that the company is temporarily suspending development of its new non-benzodiazepine anxiolytic product, Ananxyl (alpidem), in the USA. The product is already marketed in France.
Synthelabo said that its joint venture with G D Searle, Lorex Pharmaceuticals, had halted further development of the drug in the USA because of "divergent results" in clinical trials intended for inclusion in its New Drug Application to the Food and Drug Administration. Synthelabo says it plans to carry out complementary studies to discover the reason for the divergent findings before making a final decision on whether to continue with filing for US approval.
The company also said that the complementary studies may delay licensing applications in other European countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze